KPV
ALSO KNOWN AS · Lysine-proline-valine · α-MSH (11-13)
The C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity in colitis and skin inflammation models without the pigmentation effects of the parent hormone.
Mechanism
KPV appears to act intracellularly to inhibit NF-κB signalling, reducing pro-inflammatory cytokine output in intestinal epithelial and immune cells.
Status
Evidence is preclinical. There are no controlled human trials and no approved product.
PRIMARY SOURCES
- 01KPV in experimental colitis— Gastroenterology / PubMed
Educational reference only. Trial figures are protocol-condition means, not individual predictions. Investigational compounds are not approved medicines and have no legitimate consumer supply route.